Auxano Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.54M Buy
2,118
+50
+2% +$51.1K 0.48% 35
2026
Q1
$1.9M Sell
2,068
-13
-0.6% -$13.2K 0.38% 44
2025
Q4
$2.24M Sell
2,081
-92
-4% -$88K 0.44% 34
2025
Q3
$1.66M Sell
2,173
-136
-6% -$101K 0.35% 37
2025
Q2
$1.8M Buy
2,309
+108
+5% +$83.9K 0.42% 33
2025
Q1
$1.82M Sell
2,201
-49
-2% -$40.8K 0.48% 32
2024
Q4
$1.74M Buy
2,250
+578
+35% +$479K 0.44% 35
2024
Q3
$1.48M Buy
1,672
+1
+0.1% +$899 0.38% 44
2024
Q2
$1.51M Buy
1,671
+23
+1% +$18.4K 0.42% 42
2024
Q1
$1.28M Buy
1,648
+191
+13% +$136K 0.37% 46
2023
Q4
$849K Sell
1,457
-72
-5% -$42K 0.29% 58
2023
Q3
$821K Sell
1,529
-24
-2% -$12.4K 0.34% 47
2023
Q2
$533K Hold
1,553
0.21% 61
2023
Q1
$533K Buy
1,553
+88
+6% +$29.7K 0.21% 61
2022
Q4
$536K Buy
1,465
+80
+6% +$28.4K 0.24% 58
2022
Q3
$448K Buy
1,385
+28
+2% +$8.87K 0.21% 60
2022
Q2
$440K Buy
1,357
+63
+5% +$18.9K 0.22% 49
2022
Q1
$371K Hold
1,294
0.16% 54
2021
Q4
$357K Hold
1,294
0.16% 52
2021
Q3
$299K Hold
1,294
0.13% 51
2021
Q2
$297K Buy
1,294
+15
+1% +$3.01K 0.14% 52
2021
Q1
$239K Hold
1,279
0.15% 52
2020
Q4
$216K Buy
+1,279
New +$191K 0.14% 48
2020
Q3
Sell
-1,279
Closed -$210K 47
2020
Q2
$210K Buy
+1,279
New +$196K 0.17% 40

Other funds holding LLY

Auxano Advisors's LLY Position: Q2 2026 in Review

Auxano Advisors increased its Eli Lilly (LLY) stake by 2.4% in Q2 2026, buying an estimated $51.1K and bringing the position to 2,118 shares worth $2.54M. The position accounts for 0.48% of the portfolio, ranked #35.

Auxano Advisors first reported a position in LLY in Q2 2020 and has held it in 24 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Auxano Advisors held 2,118 shares of Eli Lilly worth $2.54M as of Q2 2026.
  • Auxano Advisors bought 50 Eli Lilly shares in Q2 2026, an estimated $51.1K.
  • Eli Lilly made up 0.48% of Auxano Advisors's portfolio in Q2 2026, its #35 holding.
  • Auxano Advisors first reported a position in Eli Lilly in Q2 2020 and has held it in 24 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Auxano Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.